pemetrexed pfizer (previously pemetrexed hospira)
pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.
ytracis
cis bio international - yttrium (90y) chloride - radionukliidi pildistamine - diagnostilised radiofarmatseutilised ühendid - kasutada ainult spetsiaalselt välja töötatud ja radioloogilise märgistamise jaoks selle radionukliidiga kandev-molekulide radiomärgistamiseks. radiopharmaceutical precursor - not intended for direct application to patients.
mistral® 700 wg
adama - vees dispergeeruvad graanulid - metribusiin - herbitsiidid
sodium chloride b. braun 0,9% infusioonilahus
b. braun melsungen ag - naatriumkloriid - infusioonilahus - 0,9% 50ml 20tk; 0,9% 100ml 20tk; 0,9% 250ml 10tk; 0,9% 1000ml 10tk; 0,9% 500ml 10tk
sodium chloride kabi 0,9% süsteravimi lahusti
fresenius kabi polska sp. z o.o. - naatriumkloriid - süsteravimi lahusti - 9mg 1ml 10ml 50tk; 9mg 1ml 20ml 20tk; 9mg 1ml 5ml 20tk; 9mg 1ml 5ml 50tk
sodium bicarbonate braun 8,4% infusioonilahus
b. braun melsungen ag - naatriumvesinikkarbonaat - infusioonilahus - 8,4% 250ml 10tk
sodium chloride braun 5,85% infusioonilahuse kontsentraat
b. braun melsungen ag - naatriumkloriid - infusioonilahuse kontsentraat - 5,85% 20ml 20tk